3 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood TransfusionsHemic and Lymphatic Diseases, anemia, bone marrow disorder, hematologic disorder, myelodysplastic syndromeRecruitingPhase 32026-10-08NCT06499285
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CICCNS demyelinating autoimmune disease, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hernia, Infections, Neoplasms by Site, Neuroinflammatory Diseases, Paraneoplastic Syndromes, Nervous System, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, acute transverse myelitis, autoimmune disease, autoimmune disorder of the nervous system, central nervous system disorder, central nervous system infectious disorder, central nervous system malformation, demyelinating disease, immune system disorder, injury, meningocele, myelitis, neoplasm, nervous system disorder, nervous system injury, neurodegenerative disease, paraneoplastic syndrome, spinal cord disorder, spinal cord injuryRecruitingPhase 2 / Phase 32026-06-15NCT05491525
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UCDigestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitisActive, not recruitingPhase 22025-12-15NCT05611671